Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome
Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome
复制标题
DOI：
10.1016/j.ijcard.2010.05.066
复制
发表时间：
2011-09-15
影响因子：
3.5
通讯作者：
Gatzoulis, Michael A.
中科院分区：
文献类型：
--
作者：
Tay, Edgar L. W.;Peset, Ana;Gatzoulis, Michael A.
介绍：铁缺乏是常见的紫绀型先天性心脏病（CHD），并导致运动耐量下降。目前，在紫绀型CHD中提倡铁替代，但证据有限。我们调查的安全性和有效性的铁替代疗法在此population.Methods：25铁缺乏紫绀型冠心病患者进行了前瞻性研究，2008年8月至2009年1月。口服富马酸亚铁滴定至最大剂量200 mg，每日三次。在基线和治疗3个月后进行CAMPHOR生活质量问卷、6分钟步行试验（6 MWT）和心肺运动试验。艾森曼格综合征14例，复杂性紫绀6例，Fontan循环5例。没有需要终止治疗的不良反应。治疗3个月后，血红蛋白（19.0 +/- 2.9 g/dL至20.4 +/- 2.7 g/dL，p
Introduction: Iron deficiency is common in cyanotic congenital heart disease (CHD) and results in reduced exercise tolerance. Currently, iron replacement is advocated with limited evidence in cyanotic CHD. We investigated the safety and efficacy of iron replacement therapy in this population.Methods: Twenty-five iron-deficient cyanotic CHD patients were prospectively studied between August 2008 and January 2009. Oral ferrous fumarate was titrated to a maximum dose of 200 mg thrice-daily. The CAMPHOR QoL questionnaire, 6 minute walk test (6MWT) and cardiopulmonary exercise testing were conducted at baseline and after 3 months of treatment.Results: Mean age was 39.9 +/- 10.9 years, 80% females. Fourteen had Eisenmenger syndrome, 6 complex cyanotic disease and 5 Fontan circulation. There were no adverse effects necessitating termination of treatment. After 3 months of treatment, hemoglobin (19.0 +/- 2.9 g/dL to 20.4 +/- 2.7 g/dL, p